Table 1. . Baseline characteristics of included cancer patients according to outcome (fatal vs nonfatal).
| Parameter | Patients with fatal COVID-19 infection (n = 721) | Patients with non-fatal COVID-19 infection (n = 1987) | p-value |
|---|---|---|---|
| Age, mean (standard error)† | 68.4 (0.58) | 63.8 (0.36) | <0.001 |
| Sex, n (%)† – Male – Female |
365 (58.2) 262 (41.8) |
937 (51.4) 885 (48.6) |
0.003 |
| Weight, mean (standard error)† | 74.5 (1.51) | 81.5 (0.88) | 0.006 |
| Country of occurrence, n (%) – US – Non-US |
292 (40.5) 429 (59.5) |
1272 (64) 715 (36) |
<0.001 |
| Hematological malignancy, n (%)¶ – Yes – No |
538 (74.6) 183 (25.4) |
1352 (68) 635 (32) |
0.001 |
| Type of treatment, n (%)‡ – Potentially immunosuppressive – Potentially nonimmunosuppressive |
624 (86.5) 97 (13.5) |
1629 (82) 358 (18) |
0.005 |
| Quarter of data release, n (%)§ – 2 – 3 – 4 |
197 (27.3) 222 (30.8) 302 (41.9) |
463 (23.3) 525 (26.4) 999 (50.3) |
0.001 |
†
Missing data: sex: 259; weight: 2035; age: 1123.
‡
Potentially immunosuppressive treatments include immune checkpoint inhibitors, cytotoxic chemotherapy, tyrosine kinase inhibitors, monoclonal antibodies, immunomodulatory drugs (myeloma), proteasome inhibitors and/or CDK inhibitors. Potentially nonimmunosuppressive treatments include hormonal and supportive treatments (e.g., bone-modifying agents, pain medications).
§
Q2: April to June 2020; Q3: July to September 2020; Q4: October to December 2020.
¶
Indications for treatment include leukemia, lymphoma, myeloma, myeloproliferative disorder, myelofibrosis and myelodysplasia.
COVID-19: Coronavirus disease 2019; Q: Quarter.